X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17934) 17934
Book Review (1278) 1278
Publication (678) 678
Newsletter (345) 345
Conference Proceeding (39) 39
Book Chapter (15) 15
Dissertation (6) 6
Magazine Article (5) 5
Book / eBook (3) 3
Government Document (3) 3
Newspaper Article (3) 3
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15531) 15531
animals (9292) 9292
humans (8103) 8103
female (7446) 7446
cyclophosphamide (7001) 7001
cyclophosphamide - pharmacology (6970) 6970
male (6425) 6425
mice (5895) 5895
oncology (4132) 4132
middle aged (3262) 3262
cyclophosphamide - administration & dosage (3192) 3192
adult (3065) 3065
pharmacology & pharmacy (2863) 2863
antineoplastic combined chemotherapy protocols - therapeutic use (2601) 2601
rats (2596) 2596
chemotherapy (2268) 2268
aged (2155) 2155
cyclophosphamide - therapeutic use (2022) 2022
cancer (1750) 1750
time factors (1455) 1455
dose-response relationship, drug (1346) 1346
treatment outcome (1318) 1318
immunology (1290) 1290
doxorubicin - administration & dosage (1222) 1222
breast neoplasms - drug therapy (1212) 1212
cyclophosphamide - adverse effects (1190) 1190
therapy (1161) 1161
antineoplastic combined chemotherapy protocols - adverse effects (1146) 1146
antineoplastic agents - pharmacology (1128) 1128
cyclophosphamide - toxicity (1050) 1050
adolescent (1010) 1010
mice, inbred c57bl (1000) 1000
mice, inbred balb c (975) 975
immunosuppression (952) 952
abridged index medicus (914) 914
immunosuppressive agents - pharmacology (898) 898
research (896) 896
hematology (889) 889
toxicology (854) 854
combined modality therapy (843) 843
vincristine - administration & dosage (839) 839
transplantation (824) 824
cyclophosphamide - analogs & derivatives (785) 785
antineoplastic combined chemotherapy protocols - administration & dosage (782) 782
drug administration schedule (748) 748
doxorubicin (746) 746
antineoplastic agents - therapeutic use (737) 737
medicine, research & experimental (701) 701
toxicity (700) 700
care and treatment (692) 692
prognosis (691) 691
t-lymphocytes - immunology (682) 682
medicine & public health (675) 675
disease-free survival (663) 663
analysis (652) 652
child (647) 647
expression (635) 635
apoptosis (626) 626
cells, cultured (626) 626
breast cancer (622) 622
spleen - immunology (597) 597
survival analysis (596) 596
cells (593) 593
disease models, animal (593) 593
breast neoplasms - pathology (590) 590
antineoplastic agents (580) 580
bone marrow - drug effects (578) 578
bone marrow transplantation (566) 566
rituximab (561) 561
immunotherapy (554) 554
transplantation, homologous (553) 553
prednisone - administration & dosage (552) 552
mice, inbred strains (547) 547
etoposide - administration & dosage (540) 540
pharmacology/toxicology (539) 539
health aspects (538) 538
pharmacology (535) 535
pharmacokinetics (534) 534
aged, 80 and over (512) 512
fluorouracil - administration & dosage (508) 508
risk factors (504) 504
spleen - cytology (501) 501
drug therapy, combination (499) 499
cyclophosphamide - metabolism (497) 497
survival (494) 494
survival rate (492) 492
methotrexate - administration & dosage (488) 488
kinetics (486) 486
cisplatin (480) 480
cell line, tumor (473) 473
neoplasm transplantation (469) 469
antibody formation - drug effects (468) 468
bone marrow cells (468) 468
immunosuppressive agents - therapeutic use (466) 466
cisplatin - administration & dosage (465) 465
drug therapy (459) 459
retrospective studies (459) 459
neoplasms - drug therapy (454) 454
drug synergism (452) 452
follow-up studies (445) 445
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16907) 16907
German (427) 427
Russian (350) 350
Japanese (177) 177
Chinese (151) 151
French (106) 106
Italian (64) 64
Spanish (48) 48
Polish (42) 42
Czech (13) 13
Portuguese (9) 9
Slovak (6) 6
Hungarian (3) 3
Romanian (3) 3
Ukrainian (3) 3
Hebrew (2) 2
Korean (2) 2
Norwegian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Dutch (1) 1
Persian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Letters, ISSN 0304-3835, 2016, Volume 383, Issue 2, pp. 309 - 317
Abstract In previous studies we demonstrated that targeting the nuclear exporter protein exportin-1 (CRM1/XPO1) by a selective inhibitor of nuclear export... 
Hematology, Oncology and Palliative Medicine | NHL | XPO1 | Selective inhibitors of nuclear export | SINE | CRM1 | Exportin-1 | SURVIVAL | DRUG-RESISTANCE | MODEL | CANCER | STRATEGIES | ONCOLOGY | LINE | CHOP | PROTEINS | Vincristine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Transcription Factor RelA - antagonists & inhibitors | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - enzymology | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Dexamethasone - pharmacology | Time Factors | Oxadiazoles - pharmacology | Acrylamides - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Hydrazines - pharmacology | Everolimus - pharmacology | Mice, SCID | Mice, Inbred ICR | Drug Synergism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Karyopherins - metabolism | Signal Transduction - drug effects | Transcription Factor RelA - metabolism | Tumor Burden - drug effects | Active Transport, Cell Nucleus - drug effects | Cyclophosphamide - pharmacology | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Cell Line, Tumor | Prednisone - pharmacology | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Karyopherins - antagonists & inhibitors | Doxorubicin - pharmacology | Receptors, Cytoplasmic and Nuclear - metabolism | International trade | Cyclophosphamide | Care and treatment | Dexamethasone | Analysis | Lymphomas | Prednisone | Exports | Steroids | Cancer | Drugs | TOR protein | Animal models | Laboratories | Toxicity | Xenotransplantation | Clinical trials | Cytotoxicity | Kinases | Experiments | Anticancer properties | Proteins | Cell growth | Antitumor agents | Cell cycle | Xenografts | Biocompatibility | Localization | Drug dosages | NF-κB protein | Chronic lymphatic leukemia | Hematology | Pharmacology | Chemical compounds | Patients | Lymphoma | Nuclear transport | Studies | Inhibitors | Response rates | In vivo methods and tests | Apoptosis | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects | Drug therapy | Medical treatment | Index Medicus
Journal Article
Oncogene, ISSN 0950-9232, 04/1999, Volume 18, Issue 13, pp. 2241 - 2251
Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To... 
Chemotherapy | Breast cancer | Synergy | Multiple drug effects analysis | HER-2/neu (c-erbB-2) | HER2/NEU-OVEREXPRESSING METASTATIC BREAST | synergy | GROWTH-FACTOR-RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTINEOPLASTIC AGENTS | breast cancer | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | SALIVARY-GLAND | chemotherapy | ENDOMETRIAL CANCER | CELL BIOLOGY | C-ERBB-2 PROTEIN | ONCOLOGY | multiple drug effects analysis | TUMOR NECROSIS FACTOR | GENETICS & HEREDITY | GENE-PRODUCT | Recombinant Proteins - therapeutic use | Doxorubicin - therapeutic use | Adenocarcinoma - pathology | Receptor, ErbB-2 - genetics | Humans | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vinblastine - therapeutic use | Topoisomerase II Inhibitors | Antimetabolites, Antineoplastic - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Receptor, ErbB-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | Etoposide - pharmacology | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Drug Synergism | Antimetabolites, Antineoplastic - therapeutic use | Adenocarcinoma - therapy | Antibiotics, Antineoplastic - therapeutic use | Mice, Nude | Cyclophosphamide - pharmacology | Immunization, Passive | Fluorouracil - pharmacology | Mice | Cell Cycle - drug effects | Trastuzumab | Neoplasm Transplantation | Paclitaxel - pharmacology | Antibiotics, Antineoplastic - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Transplantation, Heterologous | Fluorouracil - antagonists & inhibitors | Cyclophosphamide - therapeutic use | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Protein Processing, Post-Translational - drug effects | Female | Antineoplastic Agents - pharmacology | Thiotepa - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - biosynthesis | Etoposide - therapeutic use | Treatment Outcome | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Paclitaxel - therapeutic use | Neoplasms, Hormone-Dependent - therapy | Animals | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Vinblastine - pharmacology | Neoplasms, Hormone-Dependent - drug therapy | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, pp. e111840 - e111840
Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and... 
PROTEIN METHYLTRANSFERASES | SELECTIVE-INHIBITION | MOLECULAR SUBTYPES | APOPTOSIS | B-CELL LYMPHOMA | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | RESISTANCE | MECHANISMS | CANCER | SOMATIC MUTATIONS | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Neoplasm Transplantation | Vincristine - pharmacology | Humans | Receptors, Glucocorticoid - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Glucocorticoid - agonists | Dexamethasone - pharmacology | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical | Lymphoma, Non-Hodgkin - drug therapy | Enhancer of Zeste Homolog 2 Protein - metabolism | Random Allocation | Mice, SCID | Prednisolone - pharmacology | Animals | Cyclophosphamide - pharmacology | Lymphoma, Non-Hodgkin - metabolism | Cell Line, Tumor | Glucocorticoids - pharmacology | Prednisone - pharmacology | Doxorubicin - pharmacology | Pyridones - pharmacology | Care and treatment | Corticosteroids | Fluocinolone acetonide | Central nervous system depressants | Analysis | Histones | Models | Non-Hodgkin's lymphomas | Immunosuppressive agents | Steroids | Cancer | Signal transduction | Enzymes | Cell growth | Glucocorticoids | Research & development--R&D | Lymphomas | Mutation | Gene expression | Apoptosis | Index Medicus | Research & development | R&D
Journal Article
Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, 11/2018, Volume 123, Issue 5, pp. 567 - 576
Interstitial cystitis is a syndrome characterized by detrusor overactivity and chronic inflammation of the bladder. The mechanisms responsible for the altered... 
HEMORRHAGIC CYSTITIS | INOSITOL 1,4,5-TRISPHOSPHATE | NONMUSCLE MYOSIN-II | ADENINE-DINUCLEOTIDE PHOSPHATE | CA2+ RELEASE | CALCIUM-RELEASE | CYCLOPHOSPHAMIDE CYSTITIS | PHARMACOLOGY & PHARMACY | INTESTINAL SMOOTH-MUSCLE | LUMINAL CA2 | TOXICOLOGY | LOWER URINARY-TRACT | Amides - pharmacology | Signal Transduction | Urinary Bladder - metabolism | Enzyme Inhibitors - pharmacology | Maleimides - pharmacology | Rats | Cystitis, Interstitial - physiopathology | Ryanodine Receptor Calcium Release Channel - metabolism | rhoA GTP-Binding Protein - metabolism | Carbachol - pharmacology | Animals | rho-Associated Kinases - metabolism | Muscle Contraction - drug effects | Protein Kinase C - metabolism | Muscle Relaxants, Central - pharmacology | Inositol 1,4,5-Trisphosphate Receptors - antagonists & inhibitors | Urinary Bladder - physiopathology | Indoles - pharmacology | Pyridines - pharmacology | Sarcoplasmic Reticulum - metabolism | Cholinergic Agonists - pharmacology | Cystitis, Interstitial - metabolism | Heparin - pharmacology | Ryanodine - pharmacology | Carbachol | Cardiotonic agents | Protein kinases | Cystitis | Cardiac glycosides | Ryanodine | Protein kinase C | Calcium | Acetylcholine receptors (muscarinic) | Bladder | Smooth muscle | Intracellular signalling | Kinases | Contraction | Proteins | Signal transduction | Pathways | Sarcoplasmic reticulum | Rodents | Inhibition | Inositol 1,4,5-trisphosphate | Contractility | Muscles | RhoA protein | Sodium chloride | Muscle contraction | Rho-associated kinase | Cyclophosphamide | Inhibitors | Isoforms | Heparin | Index Medicus
Journal Article
Acta Oncologica, ISSN 0284-186X, 2003, Volume 42, Issue 4, pp. 294 - 303
Dose-response effects of fluorouracil, paclitaxel, doxorubicin, cisplatin, methotrexate, cyclophosphamide and etoposide on VEGF(165/164)-mediated angiogenesis... 
PHARMACOKINETICS | CISPLATIN | ONCOLOGY | ENDOTHELIUM | GUIDELINES | NOVO MAMMALIAN ANGIOGENESIS | RATS | TUMOR ANGIOGENESIS | GROWTH-FACTOR | CANCER | PACLITAXEL | Methotrexate - pharmacology | Neovascularization, Physiologic - drug effects | Vascular Endothelial Growth Factor A | Cyclophosphamide - administration & dosage | Injections, Intravenous | Paclitaxel - pharmacology | Vascular Endothelial Growth Factors | Humans | Male | Endothelial Growth Factors - pharmacology | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Mesentery - drug effects | Weight Gain - drug effects | Antineoplastic Agents - pharmacology | Lymphokines - pharmacology | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Etoposide - pharmacology | Rats | Etoposide - administration & dosage | Cisplatin - pharmacology | Rats, Sprague-Dawley | Mesentery - blood supply | Animals | Intercellular Signaling Peptides and Proteins - pharmacology | Cyclophosphamide - pharmacology | Methotrexate - administration & dosage | Fluorouracil - pharmacology | Doxorubicin - pharmacology | Index Medicus | Cisplatin/administration & dosage/pharmacology | Doxorubicin/administration & dosage/pharmacology | Methotrexate/administration & dosage/pharmacology | Intercellular Signaling Peptides and Proteins/pharmacology | Sprague-Dawley | Antineoplastic Agents/administration & dosage/pharmacology | Neovascularization | Physiologic/drug effects | Mesentery/blood supply/drug effects | Cyclophosphamide/administration & dosage/pharmacology | Drug | Endothelial Growth Factors/pharmacology | Etoposide/administration & dosage/pharmacology | Intravenous | Lymphokines/pharmacology | Paclitaxel/administration & dosage/pharmacology | Fluorouracil/administration & dosage/pharmacology | Injections | Weight Gain/drug effects | Dose-Response Relationship | Cancer and Oncology | Cancer och onkologi
Journal Article
The Journal of Immunology, ISSN 0022-1767, 07/2009, Volume 183, Issue 1, pp. 137 - 144
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | APOPTOSIS | ANTIINFLAMMATORY ACTIVITY | ACTIVATION | CELL-CYCLE ARREST | PROLIFERATION | METASTATIC COLORECTAL-CANCER | IN-VITRO | ONCOLOGY | ENDOTHELIAL-CELLS | PHARMACOLOGY & PHARMACY | EA.hy 926 endothelial cells | INHIBITORS | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Experimental Hematology, ISSN 0301-472X, 2017, Volume 52, pp. 65 - 71
Abstract Drug interactions may dictate the failure or success of a treatment. Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to... 
Hematology, Oncology and Palliative Medicine | Advanced Basic Science | MEDICINE, RESEARCH & EXPERIMENTAL | BUSULFAN PHARMACOKINETICS | CELLS | THERAPY | CYTO-TOXICITY | GLUTATHIONE | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | MELPHALAN ACTIVITY | MYELOID-LEUKEMIA | MULTIDRUG-RESISTANCE | HEMATOLOGY | Cyclophosphamide - analogs & derivatives | Flow Cytometry - methods | Fluoresceins - metabolism | Humans | Ethacrynic Acid - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Chlorambucil - pharmacology | Ketoconazole - pharmacology | Drug Interactions | Everolimus - pharmacokinetics | Ethacrynic Acid - pharmacokinetics | Biological Transport - drug effects | Melphalan - pharmacology | Busulfan - pharmacology | Cell Survival - drug effects | Fluoresceins - chemistry | Reproducibility of Results | Busulfan - pharmacokinetics | Everolimus - pharmacology | Chlorambucil - pharmacokinetics | Ketoconazole - pharmacokinetics | Antineoplastic Agents, Alkylating - pharmacokinetics | Sirolimus - pharmacokinetics | Sirolimus - pharmacology | Cyclophosphamide - pharmacology | Cell Line, Tumor | Melphalan - pharmacokinetics | Cyclophosphamide - pharmacokinetics | Multidrug Resistance-Associated Proteins - metabolism | Antimitotic agents | Complications and side effects | Chemotherapy | Leukemia | Drug interactions | Lymphomas | Transplantation | Drug therapy, Combination | Antineoplastic agents | Ethacrynic acid | Hematopoietic stem cells | Cancer | Index Medicus | flow cytometry | drug interactions | carboxyfluorescein | drug transporter | drug efflux method | stem cell transplantation
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2010, Volume 107, Issue 44, pp. 19084 - 19089
Reduced functional bladder capacity and concomitant increased micturition frequency (pollakisuria) are common lower urinary tract symptoms associated with... 
Edema | Receptors | Urinary bladder | Overactive bladder | Mice | Pharmacology | Urination | Genetic mutation | Cystitis | Vehicles | Transient receptor potential channels | Urothelium | ACTIVATION | NEUROGENIC INFLAMMATION | ANTAGONIST | URINARY-BLADDER | MULTIDISCIPLINARY SCIENCES | transient receptor potential channels | urothelium | LACKING TRPV4 | OVERACTIVE BLADDER | CONTRACTION | RECEPTOR POTENTIAL VANILLOID-4 | MUTATIONS | TRANSIENT | Urothelium - metabolism | Cystitis - metabolism | Rats, Wistar | Humans | Antineoplastic Agents, Alkylating - pharmacology | Cyclophosphamide - adverse effects | Cystitis - drug therapy | TRPV Cation Channels - metabolism | TRPV Cation Channels - antagonists & inhibitors | Membrane Transport Modulators - pharmacology | Urination - drug effects | Urinary Bladder - metabolism | Morpholines - pharmacology | Rats | Urothelium - physiopathology | TRPV Cation Channels - genetics | Mice, Knockout | Pyrroles - pharmacology | Animals | Cyclophosphamide - pharmacology | Urinary Bladder - physiopathology | Antineoplastic Agents, Alkylating - adverse effects | Cystitis - chemically induced | Cystitis - physiopathology | Complications and side effects | Care and treatment | Cyclophosphamide | Medical examination | Bladder | Ion channels | Diagnosis | Properties | Cysts | Medical disorders | Rodents | Cells | Quality of life | Index Medicus | Biological Sciences
Journal Article